Detrimental effects of thyroid hormone analog DITPA in the mouse heart: increased mortality with in vivo acute myocardial ischemia-reperfusion
- PMID: 21131480
- PMCID: PMC3044051
- DOI: 10.1152/ajpheart.00514.2010
Detrimental effects of thyroid hormone analog DITPA in the mouse heart: increased mortality with in vivo acute myocardial ischemia-reperfusion
Abstract
There is emerging evidence that treatment with thyroid hormone (TH) can improve postischemic cardiac function. 3,5-Diiodothyropropionic acid (DITPA), a TH analog, has been proposed to be a safer therapeutic agent than TH because of its negligible effects on cardiac metabolism and heart rate. However, conflicting results have been reported for the cardiac effects of DITPA. Importantly, recent clinical trials demonstrated no symptomatic benefit in patients with DITPA despite some improved hemodynamic and metabolic parameters. To address these issues, dose-dependent effects of DITPA were investigated in mice for baseline cardiovascular effects and postischemic myocardial function and/or salvage. Mice were treated with subcutaneous DITPA at 0.937, 1.875, 3.75, or 7.5 mg·kg(-1)·day(-1) for 7 days, and the results were compared with untreated mice for ex vivo and/or in vivo myocardial ischemia-reperfusion (I/R). DITPA had no effects on baseline body temperature, body weight, or heart rate; however, it mildly increased blood pressure. In isolated hearts, baseline contractile function was significantly impaired in DITPA-pretreated mice; however, postischemic recovery was comparable between untreated and DITPA-treated groups. In vivo baseline cardiac parameters were significantly affected by DITPA, with increased ventricular dimensions and decreased contractile function. Importantly, DITPA-treated mice demonstrated high prevalence of fatal cardiac rhythm abnormalities during in vivo ischemia and/or reperfusion. There were no improvements in myocardial infarction and postischemic fractional shortening with DITPA. Myocardial sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), phospholamban (PLB), and heat shock protein (HSP) levels remained unchanged with DITPA treatment. Thus DITPA administration impairs baseline cardiac parameters in mice and can be fatal during in vivo acute myocardial I/R.
Figures





Similar articles
-
Prevention of abnormal sarcoplasmic reticulum calcium transport and protein expression in post-infarction heart failure using 3, 5-diiodothyropropionic acid (DITPA).J Mol Cell Cardiol. 2000 Nov;32(11):1939-53. doi: 10.1006/jmcc.2000.1225. J Mol Cell Cardiol. 2000. PMID: 11040100
-
Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function.Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1551-7. doi: 10.1152/ajpheart.01293.2008. Epub 2009 Mar 13. Am J Physiol Heart Circ Physiol. 2009. PMID: 19286941 Free PMC article.
-
Expression of SERCA isoform with faster Ca2+ transport properties improves postischemic cardiac function and Ca2+ handling and decreases myocardial infarction.Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2418-28. doi: 10.1152/ajpheart.00663.2007. Epub 2007 Jul 13. Am J Physiol Heart Circ Physiol. 2007. PMID: 17630344
-
Development of a thyroid hormone analogue for the treatment of congestive heart failure.Thyroid. 1996 Oct;6(5):521-6. doi: 10.1089/thy.1996.6.521. Thyroid. 1996. PMID: 8936682 Review.
-
Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure.Thyroid. 2002 Jun;12(6):527-33. doi: 10.1089/105072502760143935. Thyroid. 2002. PMID: 12165118 Review.
Cited by
-
Thyroid hormones and cardiac remodeling.Heart Fail Rev. 2016 Jul;21(4):365-72. doi: 10.1007/s10741-016-9554-7. Heart Fail Rev. 2016. PMID: 27138258 Review.
-
American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models.Thyroid. 2014 Jan;24(1):88-168. doi: 10.1089/thy.2013.0109. Epub 2013 Dec 12. Thyroid. 2014. PMID: 24001133 Free PMC article.
-
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028. Thyroid. 2014. PMID: 25266247 Free PMC article.
-
Selective thyroid hormone receptor modulators.Indian J Endocrinol Metab. 2013 Mar;17(2):211-8. doi: 10.4103/2230-8210.109663. Indian J Endocrinol Metab. 2013. PMID: 23776891 Free PMC article.
-
Nonthyroidal illness and the cardiorenal syndrome.Nat Rev Nephrol. 2013 Oct;9(10):599-609. doi: 10.1038/nrneph.2013.170. Epub 2013 Sep 3. Nat Rev Nephrol. 2013. PMID: 23999398 Review.
References
-
- Adamson C, Maitra N, Bahl J, Greer K, Klewer S, Hoying J, Morkin E. Regulation of gene expression in cardiomyocytes by thyroid hormone and thyroid hormone analogs 3,5-diiodothyropropionic acid and CGS 23425 [N-[3,5-dimethyl-4-(4′-hydroxy-3′-isopropylphenoxy)-phenyl]-oxamic acid]. J Pharmacol Exp Ther 311: 164–171, 2004 - PubMed
-
- Carr AN, Kranias EG. Thyroid hormone regulation of calcium cycling proteins. Thyroid 12: 453–457, 2002 - PubMed
-
- Danzi S, Klein I. Thyroid hormone-regulated cardiac gene expression and cardiovascular disease. Thyroid 12: 467–472, 2002 - PubMed
-
- Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5: 513–520, 2003 - PubMed
-
- Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 12: 459–466, 2002 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous